MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure

Archives of Physiology and Biochemistry

Volumn 116, Issue 2, 2010, Pages 63-72

  Givvimani, Srikanth ^a   Tyagi, Neetu ^a   Sen, Utpal ^a   Mishra, Paras K ^a   Qipshidze, Natia ^a   Munjal, Charu ^a   Vacek, Jonathan C ^a   Abe, Oluwasegun A ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Angiostatin; Aortic banding; Capillary rarefaction; Endostatin; Endothelial; TAC; Vasculogenesis; VEGF; X ray angiography

Indexed keywords

ANGIOGENIC FACTOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL; AORTA; APOPTOSIS; ARTICLE; C57BL MOUSE; CARDIOMEGALY; HEART FAILURE; HYPERTROPHY; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; WESTERN BLOTTING; X RAY;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; AORTA; APOPTOSIS; BLOTTING, WESTERN; CARDIOMEGALY; HEART FAILURE; HYPERTROPHY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; X-RAYS;

MUS;

EID: 77951704992     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813451003652997     Document Type: Article

References (34)

1. Allard MF, Flint JD, English JC, Henning SL, Salamanca MC, Kamimura CT, English DR. (1994). Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts. J Mol Cell Cardiol 26:1551-1563
2. Baker AH, Zaltsman AB, George SJ, Newby AC. (1998). Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 101(6):1478-1487
3. Boluyt MO, O'Neill L, Meredith AL, Bing OH, Brooks WW, Conrad CH, Crow MT, Lakatta EG. 1994. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res 75(1):23-32.
4. Camp TM, Tyagi SC, Senior RM, Hayden MR, Tyagi SC. (2003). Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia 46(10):1438-1445
5. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, and Sukhatme VP. (1999). Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721-11726
6. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, and Lorell BH. (1999). Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 84:729-734
7. Dobryansky M, Galiano RD, Cetrulo Jr CL, Bhatt KA, Michaels J, Ashinoff R, Levine JP, Gurtner GC. (2004). Endostatin inhibits ischemia-induced neovascularization and increases ischemic tissue loss. Ann Plast Surg 52:512-518
8. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, et al. (2000). Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106(1):55-62.
9. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. (2000). Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19:1187-1194
10. Ferrara N, Davis-Smyth T. (1997). The biology of vascular endothelial growth factor. Endocr Rev 18:4-25.
11. Frey N, Olson EN. (2003). Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45-79.
12. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. (2006). Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol 101(3):204-213
13. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, et al. (2002). The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16:1802-1804
14. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG. (2002). Endostatin blocks vascular endothelial growth factormediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277: 27872-27879
15. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG. (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60:5410-5413
16. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClister Jr DM, Su H, Gannon J, MacGillivray C, et al. (2006). Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290(1):H232-9.
17. Lindsay ML, Maxwell P and Dunn FG. (2002). TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136-141
18. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. (2005). Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 288(2):H461-8.
19. McMurray JV, Pfeffer MA. (2005). Heart failure. The Lancet 365(9474):1877-1889
20. Norrby K. (2006). In vivo models of angiogenesis. J Cell Mol Med 10:588-612.
21. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285
22. Papaioannou VE, and Fox JG. (1993). Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci 43:189-192
23. Pouleur H, Rousseau MF, van Eyll C, Melin J, Youngblood M, Yusuf S. (1993). Cardiac mechanics during development of heart failure. SOLVD investigators. Circulation 87(5 Suppl):IV14-20.
24. Roberts JT, Wearn JT. (1941). Quantitative changes in the capillarymuscle relationship in human hearts during normal growth and hypertrophy. Am Heart J 16:617-633
25. Sang QX. (1998). Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8(3):171-177
26. Sharma MR, Tuszynski GP, Sharma MC. (2004). Angiostatininduced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem 91:398-409.
27. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115(8):2108-2118
28. Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, Bianchi C, Sellke FW. (2009). Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol 296(2):H428-34.
29. Tarui T, Miles LA, Takada Y. (2001). Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 276:39562-39568
30. Tomanek RJ. (1990). Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 15:528-533
31. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. (2001). Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152:1247-1254
32. Tummalapalli CM, Heath BJ, Tyagi SC. (2001). Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 80(4):512-521
33. Tyagi SC. (1997). Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 168(1/2):1-12.
34. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA, Curtis JJ. (1996). Posttranscriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 28(7):1415-1428